Carcinoma, Adenosquamous clinical trials
The registry lists 33 studies for Carcinoma, Adenosquamous across more than 10 countries. 7 are recruiting or about to start. 11 of them are mainly about Carcinoma, Adenosquamous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Carcinoma, Adenosquamous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (9) · Gynecologic Oncology Group (4) · M.D. Anderson Cancer Center (2) · University of South Alabama (1) · Ontario Clinical Oncology Group (OCOG) (1) · Shanghai Henlius Biotech (1) · Mayo Clinic (1) · Creative Biosciences (Guangzhou) Co., Ltd. (1)
What is being tested here
Drugs under test in Carcinoma, Adenosquamous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Jan 2027RT for Adenocarcinoma/Adenosquamous Carcinoma · Peking Union Medical College Hospital
- Jan 2027Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer · M.D. Anderson Cancer Center
- Oct 2027T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer · National Cancer Institute (NCI)
- Oct 2027APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · National Cancer Institute (NCI)
Who these studies take
Of the 6 Carcinoma, Adenosquamous studies recruiting now, 4 (67%) set no upper age limit and 2 (33%) stop at 75 or younger. 0 (0%) take children under 18. 2 (33%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 6 (100%) | 4 (67%) |
| 30 | 6 (100%) | 4 (67%) |
| 40 | 6 (100%) | 4 (67%) |
| 50 | 6 (100%) | 4 (67%) |
| 65 | 6 (100%) | 4 (67%) |
| 75 | 5 (83%) | 3 (50%) |
| 85 | 4 (67%) | 2 (33%) |
Across all 33 studies, recruiting or not: 12% stop at 75 or younger and 0% at 65; 9% take children; 58% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 33 of 33. search them.
- Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical CancerNot yet recruitingNCT07928466Phase 3
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingNCT07061977Phase 32 countries
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingNCT04858334Phase 23 countries
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingNCT02133196Phase 21 country
- PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical CancerRecruitingNCT05581121Phase 34 countries
- External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/21 country
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCRecruitingNCT05221658Phase 21 country
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerActive, not recruitingNCT00977574Phase 21 country
- Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)CompletedNCT04896073Phase 21 country
- Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical CancerActive, not recruitingNCT04622670Not applicable1 country
- Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 21 country
- RT for Adenocarcinoma/Adenosquamous CarcinomaActive, not recruitingNCT07153952Phase 1/21 country
- A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in ChinaCompletedNCT053371631 country
- Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 11 country
- Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerCompletedNCT02164461Phase 11 country
- Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell CarcinomaStatus unknownNCT04354961Phase 21 country
- Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 11 country
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 21 country
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedNCT01307631Phase 21 country
- The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized TrialCompletedNCT02394652Phase 21 country
- Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for CervixCompletedNCT01365156Phase 32 countries
- Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)CompletedNCT00895349Not applicable1 country
- Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01132820Phase 21 country
- Selumetinib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01011933Phase 21 country
- Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial CancerCompletedNCT01005329Phase 23 countries
- Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00820898Phase 21 country
- Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckTerminatedNCT00570674Phase 1/2
- Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial CancerCompletedNCT00575952Phase 11 country
- Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and NeckCompletedNCT00513383Phase 11 country
- Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine CorpusCompletedNCT00064025Phase 21 country
- Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00006011Phase 31 country
- Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma HistologyTerminatedNCT00596830Phase 326 countries
- Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical CancerTerminatedNCT01363466Phase 31 country